Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply

Affiliations

¹ George Institute for Global Health, Sydney, NSW, Australia mjardine@georgeinstitute.org.au.
² Stanford Center for Clinical Research, Stanford, CA.
³ George Institute for Global Health, Sydney, NSW, Australia.

Comment

Meg J Jardine et al. N Engl J Med. 2019.

. 2019 Sep 12;381(11):1089-1090.

doi: 10.1056/NEJMc1909687.

¹ George Institute for Global Health, Sydney, NSW, Australia mjardine@georgeinstitute.org.au.
² Stanford Center for Clinical Research, Stanford, CA.
³ George Institute for Global Health, Sydney, NSW, Australia.

No abstract available

Comment on

Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
Leslie BR, Gerwin LE. Leslie BR, et al. N Engl J Med. 2019 Sep 12;381(11):1087-1088. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509681 No abstract available.
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
Isreb M, Al-Makki A, Buatois E. Isreb M, et al. N Engl J Med. 2019 Sep 12;381(11):1088. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509682 No abstract available.
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
Lima JG, Santos MC, Simas BC. Lima JG, et al. N Engl J Med. 2019 Sep 12;381(11):1088-1089. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509683 No abstract available.
Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
Post A, Eisenga MF, Bakker SJL. Post A, et al. N Engl J Med. 2019 Sep 12;381(11):1089. doi: 10.1056/NEJMc1909687. N Engl J Med. 2019. PMID: 31509684 No abstract available.